SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as its community rallies around a shared vision, emphasizing their strong belief in the project's long-term success, particularly within the Solana ecosystem. Active community members are encouraging each other to stay focused and united, aiming to outperform other projects. The community's enthusiasm is palpable, with members expressing readiness for upcoming developments.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

SLAP is trending as the community rallies around the project's unique approach to crypto, which includes staking rewards, real-world events, and support from pro athletes. Community members highlight the team's active engagement and efforts to onboard newcomers to web3. The discussion also includes questions about the project and its overall direction.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community buzzes around potential catalysts and upcoming integrations like ZAP. Some users highlight the coin's strong community and potential for growth within the Bitcoin ecosystem, with many expressing a bullish outlook.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending with community members weighing in on potential price movements and key support levels, especially in light of recent market volatility. Some traders are capitalizing on price swings, while others are focused on the long-term potential and accumulating more $SOL. The conversation also includes discussion of Solana-based meme coins and new ETF filings.

this coin is scarce

SCARCE CRYPTO is trending as social media buzz points to a potential breakout, with community members noting its "coiled" chart pattern and "understated strength." The coin, associated with the Solana ecosystem, is being watched for a major move as participants speculate about whale accumulation and a possible surge.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Strike Coin ($STRK) is trending as the community highlights its privacy and scaling solutions, particularly its relationship with Zcash ($ZEC). Discussions focus on Starknet's potential to bring privacy to Layer 2 and its potential for significant rallies.  Some community members are also noting the current ticker may not be Starknet.

To honor the incredible bravery of Daboo, a heartfelt movement has been created to keep his memory alive The initiative celebrates Daboo's unwavering loyalty and courage while promoting causes that align with his heroic spirit, such aS animal rescue efforts, shelter funding, and pet safety awareness Through storytelling, Daboo's legacy serves as a reminder of the selfless love that animals offer to humans. By sharing his story and supporting these meaningful causes, the memory of Daboo continues to inspire kindness and compassion, ensuring his heroic act is never forgotten No Rug Pulls, No Get Rich Scams. Just Pure love for the meme coins!

Daboo

DABOO is trending as the community discusses its potential and recent price action, with some users highlighting its small supply and AI aspects. There's also discussion around potential connections to other cryptocurrencies like BTC, SOL and ETH, as well as comparison to other tokens. However, some users are also expressing concerns about bots and potential scam activity.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The 'crow with knife' meme coin is gaining traction across multiple chains, with the community emphasizing its fully circulated supply and organic growth. Discussions highlight its deflationary nature and potential staking opportunities. The community buzz reflects excitement about its potential to disrupt the meme coin landscape.

Amentum Holdings, Inc. provides mission-critical, technology-driven services in government and commercial markets. It operates through two operating segments: Critical Mission Solutions and Cyber & Intelligence. The Critical Mission Solutions segment provides test, training, and operations services for missile defense systems, IT and engineering services to defense clients and the space sector, technological solutions, including installations, decommissioning, and environmental remediation to energy clients, and other highly technical consulting solutions. The Cyber & Intelligence segment provides advanced cyber training and data analytics for government professionals, advanced communication systems and aerial mapping technologies to national security clients, and other technical services for United States defense and intelligence clients. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings (AMTM) is trending as investors discuss its substantial $44.6 billion backlog and potential long-term value, particularly with government contracts. Community chatter also revolves around options strategies and speculation regarding future deals, including potential involvement in projects like the U.S. Space Force's "Death Star." However, some traders are expressing concerns over the stock's bearish short-term trend, evidenced by its price trading below key moving averages.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around the project's ethos of perseverance, even when "everything broken." The community is expressing bullish sentiment and emphasizing its strength, while also highlighting the utility provided by Broke Perspective. There is ongoing discussion around community collaboration with $CAW, $DOG, $RAGE and others, with community members using terms like $WAGMI (We Are All Going to Make It) and calling for others to $SLAP (buy).

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Cuts Immunic (NASDAQ:IMUX) Price Target to $8.00

HC Wainwright lowered their target price on shares of Immunic from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Friday...

Immunic (NASDAQ:IMUX) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Immunic (NASDAQ:IMUX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.05...

D. Boral Capital Cuts Immunic (NASDAQ:IMUX) Price Target to $8.00

D. Boral Capital reduced their target price on Immunic from $10.00 to $8.00 and set a "buy" rating for the company in a report on Thursday...

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire NEW YORK...

Q3 Earnings Forecast for Immunic Issued By Roth Capital

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Equities researchers at Roth Capital issued their Q3 2025 EPS estimates for Immunic in a research report issued on Friday, November 7th. Roth Capital...

Immunic (NASDAQ:IMUX) Now Covered by Analysts at Roth Capital

Roth Capital began coverage on Immunic in a report on Friday. They issued a "buy" rating and a $3.00 price target on the stock...

Immunic to Participate in Industry and Investor Conferences in November

Immunic to Participate in Industry and Investor Conferences in November Immunic to Participate in Industry and Investor Conferences in November PR Newswire NEW YORK, Oct. 29, 2025 NEW YORK, Oct. 29...

– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Primary Progressive Multiple Sclerosis –– Showed Consistent Reduction of Disability Worsening in Subpopulations Without Inflammatory Lesions at Baseline in Overall Study Population; Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events in Patients Without Gadolinium-Enhancing Lesions at Baseline by 29% Compared to Placebo –&nbsp;– Reduced Annualized Rate of Thalamic Brain Volume Loss by 20% Compared to Placebo –– Confirmed Favorable Safety and Tolerability Observed in Previous Clinical Trials; No New Safety Signals Identified –– Webcast to be Held Today, April 30, at 8:00 am ET –NEW YORK, April 30, 2025 /PRNewswire/ -- <a target="_blank" rel="noopener noreferrer nofollow" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4416494-1&amp;h=1233229441&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc.">Immunic, Inc.</a>&nbsp;(Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS).&nbsp;Clinical EndpointsIn the overall PMS patient population (n=467), vidofludimus calcium reduced the relative risk of 24-week confirmed disability worsening (24wCDW) events based on changes in the expanded disability status scale (EDSS) by 20% compared to placebo. Further analyses by disease subtype demonstrated that vidofludimus calcium was associated with a 30% reduction in the relative risk of 24wCDW events in the primary progressive multiple sclerosis (PPMS) study population (n=152) compared to placebo and a respective 15% reduction in the non-active secondary progressive multiple sclerosis (naSPMS) study population (n=268). Reduction of confirmed disability worsening is widely considered to be the most recognized regulatory approval endpoint for registrational studies in progressive forms of multiple sclerosis (MS).&nbsp;Immunic believes that these reductions in 24wCDW events are remarkable in light of the overwhelming non-activity of the CALLIPER population. In support, the evidence of focal inflammatory disease (gadolinium-enhancing lesions at baseline in 6.8% of naSPMS and 17.8% of PPMS patients) and the number of on-study relapses (5.8% in the overall patient population) are lower than in most historical PMS trials.A consistent reduction of disability worsening was observed in the different subpopulations with or without inflammatory gadolinium-enhanced lesion activity at baseline and during the study. Vidofludimus calcium reduced the relative risk of 24wCDW events in patients without gadolinium-enhancing lesions at baseline by 29% compared to placebo. In historical studies, such&nbsp;patients were largely shown to not benefit from current anti-inflammatory therapies. Immunic believes the substantial effect in these patients, therefore, underlines the previously observed neuroprotective effect of Nurr1 activation by vidofludimus calcium.Magnetic Resonance Imaging (MRI) EndpointsWhile vidofludimus calcium had a modest benefit on the exploratory primary MRI endpoint (annualized rate of percent brain volume change: 5% improvement compared to placebo), vidofludimus calcium substantially reduced the annualized rate of thalamic brain volume loss by 20% in patients with PMS compared to placebo. Change in thalamic volume is considered a more sensitive MRI atrophy marker. Thalamic atrophy is prevalent in PMS and data has shown strong associations with clinical disability progression.&nbsp;The total volume of new or enlarging T2 lesions showed a substantial difference between vidofludimus calcium and placebo&nbsp;over time,&nbsp;with vidofludimus calcium decreasing and placebo increasing (mean percent change, 3.19% benefit for vidofludimus calcium (-0.22%) over placebo (+2.97%) at month 24)."The tremendous reduction of confirmed disability worsening in PMS patients is a wonderful confirmation of the objectives of this exploratory phase 2 trial. CALLIPER was designed to evaluate the clinical efficacy, safety and tolerability of vidofludimus calcium in a broad set of PMS patients to determine the suitability of advancing to a confirmatory phase 3 program," said Daniel Vitt, Ph.D., Chief Executive Officer of Immunic. "We are particularly thrilled to see such a clinically meaningful effect in the PPMS population, with a 30% reduction in the relative risk of 24-week confirmed disability worsening events, which would be the endpoint of a future phase 3 registration study, outperforming historic trials in PPMS regarding numerical reduction of disability progression events. We believe that vidofludimus calcium may represent a novel and exciting approach for people living with PMS, where there continues to be a huge unmet medical need given only one approved therapy. We look forward to discussing these results with healthcare authorities to determine appropriate next steps for vidofludimus calcium in PMS."&nbsp;"The most significant unmet need in MS continues to be the lack of safe and effective therapies that can slow or halt disease progression, especially in PPMS and non-active SPMS. Vidofludimus calcium is the only medicine in development for MS that has been shown to be a potent activator of Nurr1, which plays a key role in neuroprotection. With this unique mode of action, vidofludimus calcium could become the first real neuroprotective treatment option for patients with progressive forms of MS," added Andreas Muehler, M.D., M.B.A., Chief Medical Officer of Immunic. "In particular, the 29% reduction of 24-week confirmed disability worsening events for vidofludimus calcium over placebo in the 391 patients without gadolinium-enhancing lesions at baseline underlines the drug's breakthrough potential in addressing the high unmet need of slowing neurodegeneration in MS patients. We believe today's exciting results of the phase 2 CALLIPER trial further validate vidofludimus calcium's scientific rationale, specifically driven by the impressive numerical benefit in reducing disability worsening, which deserves to be further tested in a phase 3 registration trial. Since almost all disability events in a non-active PMS population are known to be progression independent of relapse activity (PIRA), we believe the CALLIPER results also corroborate the benefit on disability progression expected for people suffering from relapsing forms of MS, allowing for a beneficial read-through to our ongoing phase 3 ENSURE trials."&nbsp;Safety and TolerabilityThe top-line CALLIPER data set confirmed the favorable safety and tolerability profile of vidofludimus calcium already observed in previous clinical trials. No new safety signals were identified. The occurrence of treatment-emergent adverse events and serious adverse events showed a similar frequency between both treatment arms. The rate of treatment-emergent adverse events was 69.4% of vidofludimus calcium-treated patients compared with 68.5% of patients on placebo. Likewise, serious adverse events were rare and only observed in 8.1% of vidofludimus calcium-treated patients, and in 6.5% of patients on placebo. Additionally, no Hy's law range cases regarding elevations of liver enzymes were observed during the study.&nbsp;About CALLIPERCALLIPER is an international, multicenter, randomized, double-blind, placebo-controlled, exploratory phase 2 trial which enrolled 467 patients at more than 70 sites throughout North America as well as Western, Central and Eastern Europe. Patients, aged 18 to 65 years and without limitation on disease duration,&nbsp;were randomized to either 45 mg daily doses of vidofludimus calcium or placebo and treated for up to 120 weeks. CALLIPER enrolled mainly patients with PPMS (n=152/467) and naSPMS (n=268/467). All patients showed no evidence of relapse in the last 24 months before randomization. For more information, please visit: <a target="_blank" rel="noopener noreferrer nofollow" href="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</a>, NCT05054140.&nbsp;Analysis of the full CALLIPER data set is ongoing and will be presented at upcoming scientific meetings. The company's phase 3 clinical trial program of vidofludimus calcium in relapsing multiple sclerosis is ongoing and expected to be completed in 2026.Webcast Information Immunic will host a webcast today at 8:00 am ET to discuss these results. To participate in the webcast, please register in advance at:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4416494-1&amp;h=1348377319&amp;u=https%3A%2F%2Fimux.zoom.us%2Fwebinar%2Fregister%2FWN_tzX8otsFRAawwEmjwgCjeA&amp;a=https%3A%2F%2Fimux.zoom.us%2Fwebinar%2Fregister%2FWN_tzX8otsFRAawwEmjwgCjeA">https://imux.zoom.us/webinar/register/WN_tzX8otsFRAawwEmjwgCjeA</a>&nbsp;or on the "Events and Presentations" section of Immunic's website at: <a target="_blank" rel="noopener noreferrer nofollow" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4416494-1&amp;h=1241921930&amp;u=https%3A%2F%2Fir.imux.com%2Fevents-and-presentations&amp;a=ir.imux.com%2Fevents-and-presentations">ir.imux.com/events-and-presentations</a>.&nbsp;Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.&nbsp;An archived replay of the webcast will be available approximately one hour after completion on Immunic's website at: <a target="_blank" rel="noopener noreferrer nofollow" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4416494-1&amp;h=1241921930&amp;u=https%3A%2F%2Fir.imux.com%2Fevents-and-presentations&amp;a=ir.imux.com%2Fevents-and-presentations">ir.imux.com/events-and-presentations</a>.About Progressive Multiple Sclerosis While multiple sclerosis (MS) in general is an autoimmune disease characterized by immune-mediated demyelination that affects the brain, spinal cord and optic nerve, the progressive phase of the disease seems to be dominated by significant neurodegenerative mechanisms. Progressive multiple sclerosis (PMS) is a clinical form of MS characterized by gradual accrual of disability independent of relapses over time. PMS includes both primary progressive MS (PPMS) and secondary progressive MS (SPMS). PPMS is characterized by steadily worsening neurologic function from the onset of symptoms without initial relapse or remissions. SPMS is identified following an initial relapsing-remitting course, after which the disease becomes more steadily progressive, with (active SPMS) or without (non-active SPMS) MRI lesions and/or relapses present.&nbsp;About Vidofludimus Calcium (IMU-838) Vidofludimus calcium is an orally administered investigational small molecule drug being developed for chronic inflammatory and autoimmune diseases, currently in late-stage clinical trials for multiple sclerosis (MS). Uniquely, vidofludimus calcium's first-in-class, dual mode of action combines neuroprotective, anti-inflammatory and anti-viral effects to target the complex pathophysiology of MS. As a selective immune modulator, it activates the neuroprotective transcription factor, nuclear receptor-related 1 (Nurr1), which provides direct and indirect neuroprotective effects. Additionally, vidofludimus calcium achieves anti-inflammatory and anti-viral effects through highly selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). Vidofludimus calcium is currently being evaluated in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive MS, respectively. In a phase 2 clinical trial, it has shown therapeutic activity in patients suffering from relapsing-remitting MS, significantly reducing MRI lesions and demonstrating encouraging results in reducing confirmed disability worsening. Additionally, vidofludimus calcium has demonstrated clinical benefits in progressive MS patients by showing substantial reductions in the relative risks of 24-week confirmed disability progression events and in thalamic brain volume in a phase 2 clinical trial. To date, vidofludimus calcium has been exposed to approximately 2,700 individuals and has shown an attractive pharmacokinetic, safety and tolerability profile. Vidofludimus calcium is not yet licensed or approved in any country.&nbsp;About Immunic, Inc. Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, which are expected to be completed in 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: <a target="_blank" rel="noopener noreferrer nofollow" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4416494-1&amp;h=2181408004&amp;u=http%3A%2F%2Fwww.imux.com%2F&amp;a=www.imux.com">www.imux.com</a>.&nbsp;Cautionary Statement Regarding Forward-Looking Statements This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the company and further updates with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the company's subsequent filings with the SEC. Copies of these filings are available online at <a target="_blank" rel="noopener noreferrer nofollow" href="http://www.sec.gov/">www.sec.gov</a> or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.&nbsp;Contact InformationImmunic, Inc. Jessica Breu Vice President Investor Relations and Communications +49 89 2080 477 09 <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:jessica.breu@imux.com">jessica.breu@imux.com</a>US IR Contact Rx Communications Group Paula Schwartz +1 917 633 7790 <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:immunic@rxir.com">immunic@rxir.com</a>US Media Contact KCSA Strategic Communications Caitlin Kasunich +1 212 896 1241 <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:ckasunich@kcsa.com">ckasunich@kcsa.com</a>View original content to download multimedia:<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/immunic-announces-vidofludimus-calcium-reduced-risk-of-disability-worsening-by-30-in-primary-progressive-multiple-sclerosis-patients-from-phase-2-calliper-trial-302442274.html">https://www.prnewswire.com/news-releases/immunic-announces-vidofludimus-calcium-reduced-risk-of-disability-worsening-by-30-in-primary-progressive-multiple-sclerosis-patients-from-phase-2-calliper-trial-302442274.html</a>SOURCE Immunic, Inc. &nbsp;

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Others

NEW YORK, May 2, 2025 /PRNewswire/ --&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4417130-1&amp;h=2471452423&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc.">Immunic, Inc.</a>&nbsp;(Nasdaq: IMUX),&nbsp;a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences in May:&nbsp;<ul><li>May 3-6:&nbsp;Digestive Disease Week (DDW). Two abstracts discussing Immunic's phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), in patients with celiac disease, have been accepted for poster presentations at this conference in&nbsp;San Diego, CA. &nbsp;<ul><li>Poster Title:&nbsp;IMU-856 vs. Placebo Efficacy Effects in Celiac Disease Patients Are Independent of Q-MARSH Scale at Baseline</li><li>Abstract ID:&nbsp;4216653</li><li>Poster Number:&nbsp;Tu1329</li><li>Presenting Author:&nbsp;Indira Pichetto Olanda, M.D., Associate Medical Manager, Immunic</li><li>Session:&nbsp;Enteropathies — Celiac, Gluten Related and Environmental</li><li>Session Date:&nbsp;Tuesday, May 6, 2025</li><li>Session Time:&nbsp;12:30 – 1:30 pm PDT &nbsp;</li><li>Poster Title:&nbsp;Influence of Gut Epithelial Condition on the Pharmacokinetic Properties of IMU-856, an Oral Regulator of Barrier Function for the Treatment of Celiac Disease</li><li>Abstract ID:&nbsp;4219364</li><li>Poster Number:&nbsp;Tu1344</li><li>Presenting Author:&nbsp;Jacques Arend, M.D., Head of Clinical Pharmacology, Immunic</li><li>Session:&nbsp;Enteropathies — Celiac, Gluten Related and Environmental</li><li>Session Date:&nbsp;Tuesday, May 6, 2025</li><li>Session Time:&nbsp;12:30 – 1:30 pm PDT &nbsp;</li></ul></li><li>May 13-15:&nbsp;Clinical Trial Supply Forum 2025. Kimi Oanh Le, Head of Clinical Trial Supply at Immunic, will discuss the clinical trial supply chain challenges working across the Middle East and North Africa(MENA) at this forum in Brussels, Belgium. &nbsp;<ul><li>Presentation Type:&nbsp;Case Study</li><li>Case Study Title:&nbsp;Immunic Therapeutics Supply Chain Challenges Working Across MENA</li><li>Date:&nbsp;Wednesday, May 14, 2025</li><li>Time:&nbsp;10:40 am CEST (4:40 am EDT) &nbsp;</li></ul></li><li>May 28-31:&nbsp;Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2025. Members of Immunic's management, medical and preclinical teams will attend this meeting in Phoenix, AZ. The team will be available throughout the event at booth #911. Additionally, preclinical data highlighting lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), will be presented in a poster presentation. &nbsp;<ul><li>Poster Title:&nbsp;In Preclinical Models, Vidofludimus Calcium Exhibits Potential Neuroprotective Effects in Multiple Sclerosis by Modulating Nurr1</li><li>Presenting Author:&nbsp;Amelie Schreieck, Ph.D., Senior Manager Biomarker Development, Immunic</li><li>Abstract ID:&nbsp;10271</li><li>Poster Board Label:&nbsp;NDM01</li><li>Date:&nbsp;Thursday, May 29, 2025</li><li>Time:&nbsp;5:00 – 7:00 pm MST</li></ul></li></ul>All presentations will be accessible on the "Events and Presentations" section of Immunic's website at: <a target="_blank" rel="noopener noreferrer nofollow" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4417130-1&amp;h=1645169867&amp;u=https%3A%2F%2Fir.imux.com%2Fevents-and-presentations&amp;a=https%3A%2F%2Fir.imux.com%2Fevents-and-presentations">https://ir.imux.com/events-and-presentations</a>.About Immunic, Inc.Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, which are expected to be completed in 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: <a target="_blank" rel="noopener noreferrer nofollow" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4417130-1&amp;h=1489726594&amp;u=http%3A%2F%2Fwww.imux.com%2F&amp;a=www.imux.com">www.imux.com</a>.&nbsp;Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in scientific and industry conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the company's subsequent filings with the SEC. Copies of these filings are available online at <a target="_blank" rel="noopener noreferrer nofollow" href="http://www.sec.gov/">www.sec.gov</a> or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.&nbsp;Contact InformationImmunic, Inc. Jessica Breu Vice President Investor Relations and Communications +49 89 2080 477 09 <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:jessica.breu@imux.com">jessica.breu@imux.com</a>US IR Contact Rx Communications Group Paula Schwartz +1 917 633 7790 <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:immunic@rxir.com">immunic@rxir.com</a>US Media Contact KCSA Strategic Communications Caitlin Kasunich +1 212 896 1241 <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:ckasunich@kcsa.com">ckasunich@kcsa.com</a>View original content to download multimedia:<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/immunic-to-participate-in-scientific-and-industry-conferences-in-may-302444030.html">https://www.prnewswire.com/news-releases/immunic-to-participate-in-scientific-and-industry-conferences-in-may-302444030.html</a>SOURCE Immunic, Inc.

Immunic to Participate in Scientific and Industry Conferences in May

NEW YORK, May 28, 2025 /PRNewswire/ -- <a target="_blank" rel="noopener noreferrer nofollow" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4437419-1&amp;h=4199890651&amp;u=http%3A%2F%2Fwww.imux.com%2F&amp;a=Immunic%2C+Inc.">Immunic, Inc.</a> ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has commenced an underwritten public offering of (i) pre-funded warrants to purchase shares of common stock, (ii) Series A warrants to purchase shares of common stock (or pre-funded warrants) expiring on December 31, 2025, (iii) and Series B warrants to purchase shares of common stock (or pre-funded warrants) expiring five years following the issuance date. The Series A and B warrants will&nbsp;immediately&nbsp;expire in&nbsp;proportion&nbsp;to&nbsp;the&nbsp;extent that&nbsp;the corresponding&nbsp;pre-funded&nbsp;warrant&nbsp;offered&nbsp;hereby is&nbsp;exercised&nbsp;on&nbsp;or&nbsp;prior to&nbsp;September&nbsp;30,&nbsp;2025, subject to certain exceptions. All of the securities to be sold in the proposed offering will be offered by Immunic. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.&nbsp;The Company intends to use the net proceeds received from the proposed offering to fund its clinical trials and operations and for other general corporate purposes.Leerink Partners is acting as the sole bookrunner for the offering.The offering is being made by Immunic pursuant to a shelf registration statement on Form S-3 (File No. 333-275717), as amended, initially filed with the Securities and Exchange Commission (the "SEC") on November 22, 2023, which became effective on May 31, 2024. The offering is being made only by means of a preliminary prospectus supplement and the accompanying base prospectus that form a part of the registration statement. A preliminary prospectus supplement and the accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at <a target="_blank" rel="noopener noreferrer nofollow" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4437419-1&amp;h=4102798762&amp;u=https%3A%2F%2Fwww.sec.gov%2F&amp;a=www.sec.gov">www.sec.gov</a>. Copies of the preliminary prospectus supplement and the accompanying base prospectus, and when available, copies of the final prospectus supplement and the accompanying base prospectus relating to the offering, may be obtained by contacting Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:syndicate@leerink.com">syndicate@leerink.com</a>.&nbsp;This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.About Immunic, Inc.Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.&nbsp;Cautionary Note Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to consummation of the proposed offering as well as the timing and size of the proposed offering, Immunic's development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the Company and further updates with respect thereto; and the development and commercial potential of any product candidates of the Company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes, the Company's ability to close the proposed public offering, and the risk that warrants issued in this offering will not be exercised for cash in the future. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the Company's subsequent filings with the SEC. Copies of these filings are available online at <a target="_blank" rel="noopener noreferrer nofollow" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4437419-1&amp;h=4102798762&amp;u=https%3A%2F%2Fwww.sec.gov%2F&amp;a=www.sec.gov">www.sec.gov</a>&nbsp;or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.&nbsp;Contact InformationImmunic, Inc. Jessica Breu Vice President Investor Relations and Communications +49 89 2080 477 09 <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:jessica.breu@imux.com">jessica.breu@imux.com</a>US IR Contact Rx Communications Group Paula Schwartz +1 917 633 7790 <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:immunic@rxir.com">immunic@rxir.com</a>US Media Contact KCSA Strategic Communications Caitlin Kasunich +1 212 896 1241 <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:ckasunich@kcsa.com">ckasunich@kcsa.com</a>View original content to download multimedia:<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/immunic-inc-announces-proposed-public-offering-302467606.html">https://www.prnewswire.com/news-releases/immunic-inc-announces-proposed-public-offering-302467606.html</a>SOURCE Immunic, Inc.

Immunic, Inc. Announces Proposed Public Offering

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on multiple sclerosis, celiac disease and other neurologic and gastrointestinal disorders. The firm's products include IMU-838, IMU-856, and IMU-381. The company was founded in 2016 and is headquartered in New York, NY.

Immunic Inc

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.09	--	--	N/A
Q3 '25	-$0.14	-$0.13	9.30%	BEAT
Q2 '25	-$0.16	-$0.20	-26.74%	MISSED
Q1 '25	-$0.25	--	--	N/A
Q4 '24	-$0.23	--	--	N/A

IMUX
Immunic Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest IMUX News

IMUXImmunic Inc